GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abbisko Cayman Ltd (HKSE:02256) » Definitions » PS Ratio

Abbisko Cayman (HKSE:02256) PS Ratio : 99.06 (As of Jun. 01, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Abbisko Cayman PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Abbisko Cayman's share price is HK$3.17. Abbisko Cayman's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.03. Hence, Abbisko Cayman's PS Ratio for today is 99.06.

The historical rank and industry rank for Abbisko Cayman's PS Ratio or its related term are showing as below:

HKSE:02256' s PS Ratio Range Over the Past 10 Years
Min: 20.17   Med: 30.08   Max: 116.88
Current: 100.63

During the past 5 years, Abbisko Cayman's highest PS Ratio was 116.88. The lowest was 20.17. And the median was 30.08.

HKSE:02256's PS Ratio is ranked worse than
85.66% of 997 companies
in the Biotechnology industry
Industry Median: 9 vs HKSE:02256: 100.63

Abbisko Cayman's Revenue per Sharefor the six months ended in Dec. 2023 was HK$0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.03.

Back to Basics: PS Ratio


Abbisko Cayman PS Ratio Historical Data

The historical data trend for Abbisko Cayman's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbisko Cayman PS Ratio Chart

Abbisko Cayman Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
- - 77.12 - 114.06

Abbisko Cayman Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
PS Ratio Get a 7-Day Free Trial 77.12 - - - 114.06

Competitive Comparison of Abbisko Cayman's PS Ratio

For the Biotechnology subindustry, Abbisko Cayman's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abbisko Cayman's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abbisko Cayman's PS Ratio distribution charts can be found below:

* The bar in red indicates where Abbisko Cayman's PS Ratio falls into.



Abbisko Cayman PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Abbisko Cayman's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=3.17/0.032
=99.06

Abbisko Cayman's Share Price of today is HK$3.17.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Abbisko Cayman's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.03.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Abbisko Cayman  (HKSE:02256) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Abbisko Cayman PS Ratio Related Terms

Thank you for viewing the detailed overview of Abbisko Cayman's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Abbisko Cayman (HKSE:02256) Business Description

Traded in Other Exchanges
Address
Building 3, No. 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN
Abbisko Cayman Ltd is a investment holding company it operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The company has only one business segment which is the development of innovative medicines.
Executives
Lav Asset Management (hong Kong) Limited 2102 Investment manager
Shi Yi 2201 Interest of corporation controlled by you
Xu Yao-chang 2101 Beneficial owner
Yu Hongping 2501 Other
Chen Zhui 2501 Other
Futu Trustee Limited 2301 Trustee
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
Yu Hongping 2501 Other
Morgan Stanley 2201 Interest of corporation controlled by you
Temasek Life Sciences Private Limited
Trident Trust Company (hk) Limited 2301 Trustee
Computershare Hong Kong Trustees Limited 2301 Trustee
Morgan Stanley Investments (uk) 2201 Interest of corporation controlled by you
Morgan Stanley International Limited 2201 Interest of corporation controlled by you
Morgan Stanley International Holdings Inc. 2201 Interest of corporation controlled by you

Abbisko Cayman (HKSE:02256) Headlines

No Headlines